SPECT/NIRF Dual Modality Imaging for Detection of Intraperitoneal Colon Tumor with an Avidin/Biotin Pretargeting System.
SPECT/NIRF Dual Modality Imaging for Detection of Intraperitoneal Colon Tumor with an Avidin/Biotin Pretargeting System.
复制标题
使用亲和素/生物素预靶向系统检测腹膜内结肠肿瘤的 SPECT/NIRF 双模态成像
DOI：
10.1038/srep18905
复制
发表时间：
2016-01-06
影响因子：
4.6
通讯作者：
Wang F
中科院分区：
文献类型：
--
作者：
Dong C;Yang S;Shi J;Zhao H;Zhong L;Liu Z;Jia B;Wang F
我们在此描述了双模态成像腹膜内结肠肿瘤使用亲和素/生物素预靶向系统。设计、合成并表征了一种新型双模态探针99 mTc-HYNIC-lys（Cy5.5）-PEG 4-biotin。单光子发射计算机断层扫描/计算机断层扫描（SPECT/CT）成像和近红外荧光（NIRF）成像使用腹膜内LS 180人结肠腺癌异种移植物。在亲和素预注射4小时后，99 mTc-HYNIC-lys（Cy5.5）-PEG 4-biotin可以成功地使用两种模式检测腹部区域内不同大小的结肠肿瘤，并且成像结果显示无差异。生物分布研究表明，肿瘤对探针99 mTc-HYNIC-lys（Cy5.5）-PEG 4-生物素具有非常高的摄取（12.74 ± 1.89%ID/g，在p.i.并且从血液和其它正常组织中清除非常快。非预靶向小鼠中的低肿瘤摄取（在2 h p.i.肿瘤细胞染色结果显示该预靶向系统具有良好的肿瘤结合特异性。该新型探针显示出优异的成像质量、高的肿瘤-背景对比度、与肿瘤的高度结合特异性和优异的活体生物分布药代动力学的能力应证明基于抗生物素蛋白/生物素的双模态预靶向探针在肿瘤诊断和治疗的整个期间是有希望的成像工具。
We describe herein dual-modality imaging of intraperitoneal colon tumor using an avidin/biotin pretargeting system. A novel dual-modality probe,99mTc-HYNIC-lys(Cy5.5)-PEG4-biotin, was designed, synthesized and characterized. Single-photon emission computed tomography/ computed tomography (SPECT/CT) imaging and near infrared fluorescence (NIRF) imaging were developed using intraperitoneal LS180 human colon adenocarcinoma xenografts. Following avidin preinjection for 4 hours,99mTc-HYNIC-lys(Cy5.5)-PEG4-biotin could successfully detect colon tumors of different sizes inside the abdominal region using both modalities and the imaging results showed no differences. Biodistribution studies demonstrated that the tumors had a very high uptake of the probe99mTc-HYNIC-lys(Cy5.5)-PEG4-biotin (12.74 ± 1.89% ID/g at 2 h p.i.) and the clearance from blood and other normal tissues occured very fast. The low tumor uptake in the non-pretargeted mice (1.63 ± 0.50% ID/g at 2 h p.i.) and tumor cell staining results showed excellent tumor binding specificity of the pretargeting system. The ability of the novel probe to show excellent imaging quality with high tumor-to-background contrast, a high degree of binding specificity with tumors and excellentin vivobiodistribution pharmacokinetics should prove that the avidin/biotin based dual-modality pretargeting probe is a promising imaging tool during the entire period of tumor diagnosis and treatment.